Dexamethasone Zentiva: Uses, Dosage & Side Effects

What Is Dexamethasone Zentiva and What Is It Used For?

Dexamethasone is a synthetic fluorinated glucocorticoid that belongs to the corticosteroid class of medications. First synthesized in 1957 by Philip Showalter Hench and colleagues, dexamethasone has become one of the most widely used and clinically important medications in modern medicine. It is included on the World Health Organization (WHO) Model List of Essential Medicines, reflecting its critical role in healthcare systems worldwide. Dexamethasone Zentiva is the branded formulation manufactured by Zentiva, available as 0.5 mg oral tablets.

Corticosteroids are synthetic analogues of cortisol, a naturally occurring hormone produced by the adrenal cortex. Cortisol plays an essential role in numerous physiological processes, including the regulation of metabolism, immune function, cardiovascular tone, and the stress response. Dexamethasone mimics and amplifies the anti-inflammatory and immunosuppressive actions of cortisol, but with substantially greater potency and a longer duration of action. Specifically, dexamethasone has approximately 25–30 times the glucocorticoid (anti-inflammatory) potency of hydrocortisone and 5–6 times that of prednisolone. Crucially, unlike hydrocortisone and prednisolone, dexamethasone has virtually no mineralocorticoid activity, meaning it causes minimal sodium and water retention. This pharmacological profile makes dexamethasone particularly useful in clinical situations where potent anti-inflammatory effects are needed without the unwanted fluid retention associated with other corticosteroids.

The mechanism of action of dexamethasone is multifaceted and involves both genomic and non-genomic pathways. After oral administration, dexamethasone is rapidly absorbed and enters target cells where it binds to the intracellular glucocorticoid receptor (GR), a member of the nuclear receptor superfamily. The drug-receptor complex then translocates to the cell nucleus, where it binds to specific DNA sequences known as glucocorticoid response elements (GREs). This interaction modulates the transcription of hundreds of genes. Dexamethasone upregulates anti-inflammatory proteins such as lipocortin-1 (annexin A1), which inhibits phospholipase A2 and thereby reduces the production of prostaglandins and leukotrienes – key mediators of inflammation and pain. Simultaneously, dexamethasone suppresses the transcription of pro-inflammatory cytokines including tumor necrosis factor alpha (TNF-α), interleukin-1 (IL-1), interleukin-6 (IL-6), and interleukin-8 (IL-8). It also inhibits the expression of cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and various adhesion molecules, collectively resulting in a profound reduction in the inflammatory cascade.

Dexamethasone Zentiva is indicated for the treatment of numerous conditions across multiple medical specialties. In rheumatology, it is used for severe rheumatoid arthritis, systemic lupus erythematosus, polymyalgia rheumatica, and other autoimmune connective tissue diseases. In pulmonology, it treats severe asthma exacerbations, chronic obstructive pulmonary disease (COPD) flares, and organizing pneumonia. In neurology, dexamethasone is the corticosteroid of choice for reducing cerebral edema associated with brain tumors, neurosurgery, and certain forms of meningitis (particularly tuberculous meningitis). In oncology, it is widely used as an antiemetic agent in combination chemotherapy regimens, as a component of treatment protocols for multiple myeloma and lymphomas, and for the management of spinal cord compression and superior vena cava syndrome.

Additional indications include severe allergic reactions (when oral therapy is appropriate), inflammatory bowel disease exacerbations, nephrotic syndrome, organ transplant rejection prophylaxis, and endocrine disorders such as congenital adrenal hyperplasia and adrenal insufficiency. Dexamethasone also has important diagnostic applications, most notably the dexamethasone suppression test used to evaluate the hypothalamic-pituitary-adrenal (HPA) axis in the investigation of Cushing syndrome. In obstetrics, dexamethasone is administered to pregnant women at risk of preterm delivery (between 24 and 34 weeks of gestation) to accelerate fetal lung maturation and reduce the incidence and severity of respiratory distress syndrome in premature infants.

Perhaps most significantly in recent medical history, dexamethasone emerged as a cornerstone treatment for severe COVID-19 following the landmark RECOVERY trial (Randomised Evaluation of COVID-19 Therapy), published in the New England Journal of Medicine in 2021. This large-scale, open-label, controlled clinical trial enrolled over 6,400 hospitalized patients with COVID-19 across 176 hospitals in the United Kingdom. The trial demonstrated that dexamethasone 6 mg once daily (oral or intravenous) for up to 10 days reduced 28-day mortality by approximately one-third (29.3%) in patients requiring invasive mechanical ventilation and by approximately one-fifth (23.3%) in patients receiving supplemental oxygen without ventilation. Based on these findings, the WHO issued a strong recommendation for dexamethasone in the treatment of patients with severe and critical COVID-19, making it the first treatment proven to reduce COVID-19 mortality.

What Should You Know Before Taking Dexamethasone Zentiva?

Contraindications

Dexamethasone Zentiva must not be used in patients with known hypersensitivity to dexamethasone or to any of the excipients in the formulation. Absolute contraindications include systemic fungal infections (as corticosteroids can exacerbate and disseminate fungal disease), concurrent administration of live or live-attenuated vaccines (as immunosuppression may lead to disseminated infection from the vaccine organism), and cerebral malaria. Dexamethasone should not be used to treat viral infections (such as herpes simplex keratitis) unless concurrent appropriate antiviral therapy is administered, as corticosteroids can promote viral replication and dissemination.

Relative contraindications, where dexamethasone may be used if the potential benefit outweighs the risk under close medical supervision, include active or latent tuberculosis (requires concurrent anti-tuberculous therapy), active or suspected gastrointestinal perforation, diverticulitis, fresh intestinal anastomoses, peptic ulcer disease (increased risk of perforation and hemorrhage), uncontrolled hypertension, congestive heart failure, recent myocardial infarction (corticosteroids may impair myocardial healing), uncontrolled diabetes mellitus, and myasthenia gravis (initial worsening may occur). Patients with a history of psychosis or severe mood disorders should be monitored closely, as corticosteroids can precipitate or exacerbate psychiatric symptoms.

Warnings and Precautions

One of the most critical safety considerations with dexamethasone is the risk of adrenal suppression. The hypothalamic-pituitary-adrenal (HPA) axis can be suppressed with as little as 5–7 days of pharmacological corticosteroid therapy, though clinically significant suppression is more common after 2–3 weeks of continuous use. Abrupt withdrawal after prolonged therapy can precipitate acute adrenal insufficiency (adrenal crisis), a potentially life-threatening condition characterized by hypotension, hypoglycemia, nausea, vomiting, fever, and cardiovascular collapse. For this reason, dexamethasone must always be tapered gradually after prolonged use. The rate of tapering depends on the dose used, the duration of treatment, and the individual patient's response, but typically involves reducing the dose by 0.5–1 mg every 1–2 weeks under medical supervision.

Immunosuppression is another major concern with dexamethasone therapy. By suppressing both innate and adaptive immune responses, dexamethasone increases susceptibility to bacterial, viral, fungal, and parasitic infections. Infections may be more severe and atypical in presentation, making diagnosis more difficult. Patients receiving dexamethasone should avoid close contact with individuals who have active infections, particularly chickenpox (varicella) and measles, as these infections can be fatal in immunosuppressed individuals. Non-immune patients exposed to varicella or measles while on dexamethasone should receive passive immunization with varicella-zoster immunoglobulin (VZIG) or normal immunoglobulin, respectively, and may require antiviral treatment.

Dexamethasone affects glucose metabolism and can cause or worsen hyperglycemia. Patients with pre-existing diabetes mellitus may require adjustment of their antidiabetic medication (insulin or oral hypoglycemics), and blood glucose monitoring should be intensified. Dexamethasone can also unmask latent diabetes in predisposed individuals. Long-term therapy carries additional metabolic risks including dyslipidemia (elevated cholesterol and triglycerides), central obesity, and the development of full Cushing syndrome (characterized by moon face, buffalo hump, abdominal striae, skin thinning, and muscle weakness).

Pregnancy and Breastfeeding

Dexamethasone should only be used during pregnancy when the potential benefit justifies the potential risk to the fetus. Unlike prednisolone, which is largely inactivated by placental 11-beta-hydroxysteroid dehydrogenase type 2, dexamethasone crosses the placenta efficiently and reaches the fetus in pharmacologically active concentrations. This property is clinically exploited when dexamethasone is administered to promote fetal lung maturation in anticipated preterm delivery, but it also means that prolonged maternal use can affect fetal development. Animal studies and human observational data have associated first-trimester corticosteroid exposure with a small increased risk of cleft palate, though the absolute risk remains low. Prolonged use during pregnancy has been associated with intrauterine growth restriction, and neonates born to mothers who have received substantial doses during pregnancy may exhibit transient adrenal suppression requiring monitoring and supportive care.

Dexamethasone is excreted in breast milk. While the amounts present in breast milk following low-dose maternal therapy are generally considered unlikely to cause adverse effects in the breastfed infant, high-dose or prolonged maternal therapy could potentially suppress adrenal function or affect growth in the nursing infant. The decision to continue or discontinue breastfeeding during dexamethasone therapy should be made in consultation with a healthcare provider, weighing the benefits of breastfeeding against the potential risk of corticosteroid exposure to the infant. If high doses are necessary, timing feeds to minimize peak drug levels in milk (typically 1–2 hours post-dose) may reduce infant exposure.

How Does Dexamethasone Zentiva Interact with Other Drugs?

Dexamethasone is primarily metabolized by cytochrome P450 3A4 (CYP3A4), one of the most important drug-metabolizing enzymes in the human body. This metabolic pathway creates the potential for numerous pharmacokinetic drug interactions. Additionally, the pharmacological effects of dexamethasone on glucose metabolism, electrolyte balance, immune function, and blood coagulation create additional pharmacodynamic interaction opportunities. Healthcare providers should carefully review all concurrent medications before initiating dexamethasone therapy and throughout the treatment course.

Major Interactions

Minor Interactions

Several additional interactions are worth noting, though they are generally less clinically significant. Antacids and cholestyramine may reduce the absorption of oral dexamethasone if taken simultaneously; separating administration by at least 2 hours can minimize this effect. Dexamethasone may reduce the serum concentration of isoniazid, potentially affecting the efficacy of tuberculosis treatment. Concurrent use with fluoroquinolone antibiotics (such as ciprofloxacin and levofloxacin) may increase the risk of tendon disorders, including tendon rupture, particularly in elderly patients. Ciclosporin (cyclosporine) levels may be altered by concurrent dexamethasone use, and there is also a possible increased risk of seizures with the combination; close monitoring of ciclosporin blood levels is recommended.

Hormonal contraceptives containing estrogen may increase the half-life and reduce the clearance of dexamethasone, potentially enhancing its effects. Patients on long-term dexamethasone therapy may have a blunted response to skin testing (tuberculin test, allergy skin prick tests), which should be considered when interpreting results. Alcohol consumption during dexamethasone therapy may increase the risk of gastrointestinal irritation and bleeding, and patients should be advised to limit alcohol intake.

What Is the Correct Dosage of Dexamethasone Zentiva?

The dosage of Dexamethasone Zentiva is highly individualized and depends on the specific condition being treated, its severity, the patient's clinical response, and the anticipated duration of therapy. There is no single “standard” dose. The overarching principle guiding corticosteroid therapy is to use the lowest effective dose for the shortest possible duration to achieve the desired therapeutic effect while minimizing the risk of adverse effects. Dexamethasone is typically administered as a single daily dose in the morning (before 9:00 AM) to align with the physiological circadian rhythm of endogenous cortisol secretion, which peaks in the early morning hours. Morning dosing helps preserve the natural HPA axis rhythm and may reduce the risk of insomnia, which is a common side effect of corticosteroid therapy.

Adults

Children

Pediatric dosing of dexamethasone is typically weight-based and condition-specific. For croup (laryngotracheobronchitis), a single dose of 0.15–0.6 mg/kg (maximum 10 mg) is the standard treatment. For bacterial meningitis in children, the recommended dose is 0.15 mg/kg every 6 hours for 4 days, initiated before or with the first dose of antibiotics. In children with acute lymphoblastic leukemia (ALL), dexamethasone is used as part of induction and maintenance chemotherapy protocols at doses determined by the specific treatment regimen. Growth monitoring is essential in children receiving prolonged corticosteroid therapy, as dexamethasone can suppress linear growth. Catch-up growth may occur after discontinuation, but prolonged or high-dose use during critical growth periods may result in permanent growth impairment.

Elderly

Elderly patients are more susceptible to the adverse effects of corticosteroids, including osteoporosis (with increased fracture risk), diabetes mellitus, hypertension, skin fragility, and infections. The lowest effective dose should be used, and the duration of therapy should be minimized. Bone density assessment should be performed before initiating long-term therapy, and prophylactic measures against osteoporosis (calcium, vitamin D supplementation, and potentially bisphosphonate therapy) should be considered. Blood glucose and blood pressure monitoring should be more frequent in elderly patients. Mental state should also be monitored, as elderly patients may be more vulnerable to corticosteroid-induced confusion, memory impairment, and psychiatric disturbances.

Missed Dose

If you miss a dose of Dexamethasone Zentiva, take it as soon as you remember on the same day. If it is already close to the time for your next scheduled dose, skip the missed dose and resume your normal dosing schedule. Do not take a double dose to make up for a missed one. If you frequently forget doses, consider setting an alarm or using a pill organizer. Consistent daily dosing is important for maintaining therapeutic efficacy and preventing disease flares. If you are unsure about what to do after missing a dose, contact your doctor or pharmacist for advice.

Overdose

Acute overdose with dexamethasone is rarely life-threatening. Symptoms of acute overdose may include nausea, vomiting, hyperglycemia, glycosuria, anxiety, agitation, and mood disturbances. Treatment is supportive, as there is no specific antidote for corticosteroid overdose. Blood glucose should be monitored and managed as needed. In cases of chronic overexposure (excessive dosing over prolonged periods), the clinical features of Cushing syndrome will develop, including weight gain (particularly central adiposity), moon face, skin thinning with easy bruising, purple striae, muscle weakness, osteoporosis, hypertension, and hyperglycemia. Management of chronic overdose involves gradual dose reduction under medical supervision, with monitoring for adrenal insufficiency during the tapering process. In case of suspected overdose, contact your local poison control center or seek immediate medical attention.

What Are the Side Effects of Dexamethasone Zentiva?

Like all corticosteroids, dexamethasone can cause a wide range of adverse effects. The likelihood and severity of side effects are closely related to the dose used and the duration of treatment. Short courses (less than 2 weeks) at moderate doses are generally well-tolerated, while prolonged therapy at higher doses carries a substantially greater risk of both common and serious adverse effects. It is important to understand that most side effects are dose-dependent and potentially reversible upon dose reduction or discontinuation, though some (such as osteoporotic fractures, avascular necrosis, and cataracts) may cause permanent damage.

The frequency classifications below are based on published literature, regulatory summaries of product characteristics (SmPCs), and post-marketing surveillance data from the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). Individual susceptibility to side effects varies considerably, and patients should report any new or worsening symptoms to their healthcare provider promptly.

Long-term side effects of particular clinical concern include osteoporosis, which develops due to corticosteroid-induced suppression of osteoblast function and increased osteoclast activity. Bone loss is most rapid in the first 6–12 months of therapy. The British National Formulary (BNF) and the American College of Rheumatology recommend bone density assessment and prophylactic treatment with calcium (1,000–1,200 mg/day), vitamin D (800–1,000 IU/day), and, in high-risk patients, bisphosphonate therapy for all patients anticipated to receive corticosteroids for more than 3 months.

Psychiatric effects range from mild mood elevation and insomnia (which are common) to severe depression, psychosis, and delirium (which are rare but serious). Risk factors for severe psychiatric reactions include high doses, previous psychiatric history, and female sex. Symptoms typically emerge within the first few weeks of treatment and usually resolve upon dose reduction or discontinuation, though some patients may require psychiatric treatment.

How Should You Store Dexamethasone Zentiva?

Dexamethasone Zentiva tablets should be stored at room temperature, not exceeding 25°C (77°F). The tablets should be kept in their original packaging (blister pack or container) to protect them from light and moisture, both of which can degrade the active ingredient over time and reduce the medication's potency and stability. Do not transfer the tablets to another container unless it provides equivalent protection from light and moisture.

As with all medications, Dexamethasone Zentiva must be kept out of the sight and reach of children. Accidental ingestion of corticosteroids by children can cause significant adverse effects, including adrenal suppression, hyperglycemia, and behavioral changes. If accidental ingestion by a child is suspected, contact your local poison control center or emergency department immediately.

Do not use Dexamethasone Zentiva after the expiry date printed on the packaging (abbreviated EXP). The expiry date refers to the last day of the stated month. Expired medications may have reduced potency and should not be relied upon for therapeutic effect. Do not dispose of medications via household waste or wastewater. Return any unused or expired tablets to your pharmacy for safe disposal in accordance with local environmental regulations. Proper disposal of medications helps protect the environment and prevents accidental exposure to others.

What Does Dexamethasone Zentiva Contain?

The active substance in Dexamethasone Zentiva is dexamethasone. Each tablet contains 0.5 mg of dexamethasone. Dexamethasone has the chemical name 9-fluoro-11β,17,21-trihydroxy-16α-methylpregna-1,4-diene-3,20-dione and belongs to the class of fluorinated glucocorticoids. The molecular formula is C₂₂H₂₉FO₅ and the molecular weight is 392.46 g/mol. It is a white to practically white, odorless, crystalline powder that is practically insoluble in water but freely soluble in acetone and ethanol.

The excipients (inactive ingredients) in the tablet formulation serve various pharmaceutical purposes. Typical excipients in dexamethasone tablets include lactose monohydrate (a filler/diluent that provides bulk to the tablet), microcrystalline cellulose (a binder and disintegrant that aids tablet formation and dissolution), maize starch or pregelatinized starch (disintegrants that help the tablet break down in the gastrointestinal tract), magnesium stearate (a lubricant that prevents the tablet from sticking to manufacturing equipment), and colloidal anhydrous silica (a glidant that improves powder flow during manufacturing). The exact excipient composition may vary between different batches and formulations; patients should refer to the patient information leaflet included with their specific medication for the complete list.

Patients with known intolerance to lactose should be aware that this product contains lactose monohydrate. If you have been told by your doctor that you have an intolerance to some sugars, consult your doctor before taking this medication. The lactose content per tablet is generally small, and most patients with mild lactose intolerance tolerate the amounts present in oral tablet formulations without difficulty, but patients with severe lactose intolerance or galactose intolerance should discuss this with their pharmacist or prescriber.